Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine

This publication has 12 references indexed in Scilit:

• The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
  Clinical Cancer Research, 2004
• Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells
  Molecular and Cellular Biology, 2004
• Gene Silencing in Cancer in Association with Promoter Hypermethylation
  New England Journal of Medicine, 2003
• Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
  JNCI Journal of the National Cancer Institute, 2003
• Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases
  Journal of Molecular Biology, 2002
• Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogs
  Journal of Medicinal Chemistry, 1991
• Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
  European Journal of Drug Metabolism and Pharmacokinetics, 1991
• LAGRAN program for area and moments in pharmacokinetic analysis
  Computer Programs in Biomedicine, 1983
• A Bayesian extension of the minimum AIC procedure of autoregressive model fitting
  Biometrika, 1979
• A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation
  Journal of Pharmacokinetics and Biopharmaceutics, 1978